DK2632954T3 - Midler og fremgangsmåder til behandling af dlbcl - Google Patents
Midler og fremgangsmåder til behandling af dlbcl Download PDFInfo
- Publication number
- DK2632954T3 DK2632954T3 DK11787633.4T DK11787633T DK2632954T3 DK 2632954 T3 DK2632954 T3 DK 2632954T3 DK 11787633 T DK11787633 T DK 11787633T DK 2632954 T3 DK2632954 T3 DK 2632954T3
- Authority
- DK
- Denmark
- Prior art keywords
- dose
- composition
- dlbcl
- antibody
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Carbon And Carbon Compounds (AREA)
Claims (18)
- MIDLER OG FREMGANGSMÅDER TIL BEHANDLING AF DLBCL Patentkrav1. Sammensætning, som omfatter et CD19xCD3-bispecifikt antistof til anvendelse ved en fremgangsmåde til behandling af tumormasse i lymfeknudevæv og/eller ekstranodalt lymfom forårsaget af diffust storcellet B-cellelymfom (DLBCL) hos en patient, hvor fremgangsmåden endvidere omfatter administration af mindst ét glucocorticoid.
- 2. Sammensætning til anvendelsen ifølge krav 1, hvor tumormassen er kendetegnet ved tumorer med en størrelse på mere end 10 x 10 mm.
- 3. Sammensætning til anvendelsen ifølge krav 1 eller 2, hvor lymfeknudevævet indbefatter lymfeknuder og/eller milt.
- 4. Sammensætning til anvendelsen ifølge krav 1 eller 2, hvor det ekstranodale lymfom indbefatter centralnervesystemet (CNS), hudvæv, bryst, lungerne, leveren, mave-tarm-kanalen, urogenitalkanalen, øjenvæv, knoglemarv og/eller knogler.
- 5. Sammensætning til anvendelsen ifølge et hvilket som helst af de foregående krav, hvor en første dosis af sammensætningen administreres i et første tidsrum, og en anden dosis af sammensætningen efterfølgende administreres i et andet tidsrum, hvor den anden dosis er større end den første dosis.
- 6. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den første dosis er på mellem 1 og 15 pg/m2/d.
- 7. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den anden dosis er på mellem 15 og 60 pg/m2/d.
- 8. Sammensætning til anvendelsen ifølge krav 5, hvilken anvendelse endvidere, efter administration af en første og en anden dosis i et første og et andet tidsrum, omfatter administration af en tredje dosis af sammensætningen i et tredje tidsrum.
- 9. Sammensætning til anvendelsen ifølge krav 8, hvor det tredje tidsrum er længere end det første og det andet tidsrum, hvorved den anden dosis er større end den første dosis.
- 10. Sammensætning til anvendelsen ifølge krav 8 eller 9, hvor den tredje dosis er større end den første og den anden dosis.
- 11. Sammensætning til anvendelsen ifølge et hvilket som helst af kravene 8-10, hvor den første dosis er på mellem 1 og 15 pg/m2/d, idet 5 pg/m2/d foretrækkes.
- 12. Sammensætning til anvendelsen ifølge et hvilket som helst af kravene 8-11, hvor den anden dosis er på mellem 1 og 15 pg/m2/d, idet 15 pg/m2/d foretrækkes.
- 13. Sammensætning til anvendelsen ifølge et hvilket som helst af kravene 8-12, hvor den tredje dosis er på mellem 15 og 60 pg/m2/d, idet 60 pg/m2/d foretrækkes.
- 14. Sammensætning til anvendelsen ifølge et hvilket som helst af kravene 1-4, hvor antistoffet under behandling doseres med en konstant dosis valgt fra gruppen bestående af 5 pg/m2/d, 15 pg/m2/d og 60 pg/m2/d, idet 60 pg/m2/d foretrækkes.
- 15. Sammensætning til anvendelsen ifølge krav 1, hvor glucocorticoidet er valgt fra gruppen bestående af mindst én af cortison, cortisol, cloprednol, prednison, prednisolon, methylprednisolon, deflazacort, fluocortolon, triamcinolon, dexamethason, og betamethason, flusticasonpropionat, triamcinolonacetonid, idet dexamethason foretrækkes.
- 16. Sammensætning til anvendelse ifølge krav 15, hvor glucocorticoidet administreres inden administrationen af det CD19xCD3-bispecifikke antistof.
- 17. Sammensætning til anvendelse ifølge krav 16, hvor glucocorticoidet administreres mellem 6 og 48 timer inden administrationen af det CD19xCD3-bispecifikke antistof, fortrinsvis mellem 6 og 12 timer.
- 18. Sammensætning til anvendelsen ifølge krav 1, hvor patienten er behandlingsrefraktær over for kemoterapi eller eksperimentel kemoterapi og/eller har recidiv efter behandling med kemoterapi eller eksperimentel kemoterapi.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40710710P | 2010-10-27 | 2010-10-27 | |
| PCT/EP2011/068851 WO2012055961A1 (en) | 2010-10-27 | 2011-10-27 | Means and methods for treating dlbcl |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK2632954T3 true DK2632954T3 (da) | 2016-02-01 |
| DK2632954T4 DK2632954T4 (da) | 2021-08-09 |
Family
ID=45023802
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18164175.4T DK3412687T3 (da) | 2010-10-27 | 2011-10-27 | Fremgangsmåder til behandling af dlbcl |
| DK11787633.4T DK2632954T4 (da) | 2010-10-27 | 2011-10-27 | Midler og fremgangsmåder til behandling af dlbcl |
| DK15195076.3T DK3018145T3 (da) | 2010-10-27 | 2011-10-27 | Midler og fremgangsmåder til behandling af dlbcl |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18164175.4T DK3412687T3 (da) | 2010-10-27 | 2011-10-27 | Fremgangsmåder til behandling af dlbcl |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15195076.3T DK3018145T3 (da) | 2010-10-27 | 2011-10-27 | Midler og fremgangsmåder til behandling af dlbcl |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US9192665B2 (da) |
| EP (3) | EP3412687B1 (da) |
| JP (3) | JP5997168B2 (da) |
| KR (1) | KR101889995B1 (da) |
| CN (2) | CN103459425B (da) |
| AU (1) | AU2011322581B2 (da) |
| CA (1) | CA2815119C (da) |
| CL (1) | CL2013001138A1 (da) |
| CR (1) | CR20130245A (da) |
| CY (3) | CY1117155T1 (da) |
| DK (3) | DK3412687T3 (da) |
| EA (1) | EA032139B1 (da) |
| ES (3) | ES2675299T3 (da) |
| HR (2) | HRP20151444T4 (da) |
| HU (3) | HUE027678T2 (da) |
| IL (3) | IL225924A (da) |
| LT (2) | LT3412687T (da) |
| MA (1) | MA34619B1 (da) |
| ME (1) | ME02311B (da) |
| MY (1) | MY163057A (da) |
| NZ (2) | NZ609201A (da) |
| PH (1) | PH12013500826A1 (da) |
| PL (3) | PL2632954T5 (da) |
| PT (3) | PT3018145T (da) |
| RS (3) | RS54525B2 (da) |
| SG (1) | SG189869A1 (da) |
| SI (3) | SI3412687T1 (da) |
| SM (3) | SMT201800319T1 (da) |
| TR (1) | TR201808019T4 (da) |
| UA (1) | UA111175C2 (da) |
| WO (1) | WO2012055961A1 (da) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1874821T3 (pl) | 2005-04-26 | 2013-09-30 | Trion Pharma Gmbh | Kombinacja przeciwciał i glikokortykoidów do leczenia raka |
| CN103459425B (zh) * | 2010-10-27 | 2015-11-25 | 安进研发（慕尼黑）股份有限公司 | 用于治疗dlbcl的组合物 |
| EA026075B1 (ru) | 2010-11-10 | 2017-02-28 | Эмджен Рисерч (Мьюник) Гмбх | Предотвращение неблагоприятных эффектов, вызванных cd3-специфическими связывающими доменами |
| JO3529B1 (ar) * | 2013-02-08 | 2020-07-05 | Amgen Res Munich Gmbh | مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد |
| CN105829349B (zh) | 2013-10-15 | 2023-02-03 | 斯克利普斯研究所 | 肽嵌合抗原受体t细胞开关和其用途 |
| US10800828B2 (en) | 2015-03-26 | 2020-10-13 | The Scripps Research Institute | Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer |
| US11091546B2 (en) | 2015-04-15 | 2021-08-17 | The Scripps Research Institute | Optimized PNE-based chimeric receptor T cell switches and uses thereof |
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| MY196631A (en) * | 2015-10-13 | 2023-04-24 | Eureka Therapeutics Inc | Antibody Agents Specific for Human Cd19 and uses Thereof |
| WO2018014001A1 (en) | 2016-07-14 | 2018-01-18 | Fred Hutchinson Cancer Research Center | Multiple bi-specific binding domain constructs with different epitope binding to treat cancer |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018067993A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| EP3529268B1 (en) | 2016-10-19 | 2025-02-26 | The Scripps Research Institute | Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| WO2020099513A1 (en) * | 2018-11-13 | 2020-05-22 | Lipoxen Technologies Limited | Glycopolysialylation of blinatumomab |
| CN118593691A (zh) * | 2019-05-03 | 2024-09-06 | 凯德药业股份有限公司 | 施用嵌合抗原受体免疫疗法的方法 |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| JP7489407B2 (ja) | 2019-05-21 | 2024-05-23 | ノバルティス アーゲー | Ｃｄ１９結合分子及びその使用 |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| WO2022117799A2 (en) * | 2020-12-04 | 2022-06-09 | Morphosys Ag | Anti-cd19 combination therapy |
| AU2022214319A1 (en) | 2021-01-28 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| EP4507790A1 (en) | 2022-04-11 | 2025-02-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| CN120857940A (zh) | 2023-02-17 | 2025-10-28 | 瑞泽恩制药公司 | 对cd3/taa双特异性抗体有反应的诱导型nk细胞 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| US7112324B1 (en) | 1998-04-21 | 2006-09-26 | Micromet Ag | CD 19×CD3 specific polypeptides and uses thereof |
| JP2008501621A (ja) | 2003-05-31 | 2008-01-24 | マイクロメット アクツィエン ゲゼルシャフト | Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物 |
| US10000574B2 (en) | 2003-11-28 | 2018-06-19 | Amgen Research (Munich) Gmbh | Compositions comprising polypeptides |
| HUE025945T2 (en) | 2005-02-15 | 2016-07-28 | Univ Duke | Anti-CD19 antibodies and their applications in oncology |
| PL1874821T3 (pl) * | 2005-04-26 | 2013-09-30 | Trion Pharma Gmbh | Kombinacja przeciwciał i glikokortykoidów do leczenia raka |
| CN101331151A (zh) * | 2005-12-16 | 2008-12-24 | 麦克罗梅特股份公司 | 治疗肿瘤性疾病的方式和方法 |
| HRP20150175T1 (en) * | 2005-12-16 | 2015-03-27 | Amgen Research (Munich) Gmbh | Means and methods for the treatment of tumorous diseases |
| RU2495882C2 (ru) | 2006-09-08 | 2013-10-20 | Медиммун, Ллк. | Гуманизированные антитела к cd19 и их применение для лечения онкологического, связанного с трансплантацией и аутоиммунного заболевания |
| RU2769948C2 (ru) | 2007-04-03 | 2022-04-11 | Эмджен Рисерч (Мьюник) Гмбх | CD3-Эпсилон-связывающий домен с межвидовой специфичностью |
| KR101695327B1 (ko) * | 2008-11-07 | 2017-01-11 | 암젠 리서치 (뮌헨) 게엠베하 | 급성 림프구성 백혈병의 치료방법 |
| RS54655B2 (sr) | 2009-10-27 | 2021-04-29 | Amgen Res Munich Gmbh | Dozni režim za primenu cd19xcd3 bispecifičnog antitela |
| CN103459425B (zh) * | 2010-10-27 | 2015-11-25 | 安进研发（慕尼黑）股份有限公司 | 用于治疗dlbcl的组合物 |
-
2011
- 2011-10-27 CN CN201180063222.2A patent/CN103459425B/zh active Active
- 2011-10-27 PT PT151950763T patent/PT3018145T/pt unknown
- 2011-10-27 US US13/881,889 patent/US9192665B2/en active Active
- 2011-10-27 ES ES15195076.3T patent/ES2675299T3/es active Active
- 2011-10-27 WO PCT/EP2011/068851 patent/WO2012055961A1/en not_active Ceased
- 2011-10-27 HU HUE11787633A patent/HUE027678T2/en unknown
- 2011-10-27 CA CA2815119A patent/CA2815119C/en active Active
- 2011-10-27 DK DK18164175.4T patent/DK3412687T3/da active
- 2011-10-27 RS RS20160027A patent/RS54525B2/sr unknown
- 2011-10-27 MY MYPI2013001269A patent/MY163057A/en unknown
- 2011-10-27 PH PH1/2013/500826A patent/PH12013500826A1/en unknown
- 2011-10-27 PL PL11787633T patent/PL2632954T5/pl unknown
- 2011-10-27 CN CN201510672546.6A patent/CN105251003B/zh active Active
- 2011-10-27 NZ NZ609201A patent/NZ609201A/en unknown
- 2011-10-27 RS RS20200368A patent/RS60094B1/sr unknown
- 2011-10-27 MA MA35841A patent/MA34619B1/fr unknown
- 2011-10-27 SM SM20180319T patent/SMT201800319T1/it unknown
- 2011-10-27 PT PT117876334T patent/PT2632954E/pt unknown
- 2011-10-27 KR KR1020137013384A patent/KR101889995B1/ko active Active
- 2011-10-27 SI SI201131861T patent/SI3412687T1/sl unknown
- 2011-10-27 SI SI201131489T patent/SI3018145T1/en unknown
- 2011-10-27 DK DK11787633.4T patent/DK2632954T4/da active
- 2011-10-27 HR HRP20151444TT patent/HRP20151444T4/hr unknown
- 2011-10-27 ES ES11787633T patent/ES2563439T5/es active Active
- 2011-10-27 HU HUE18164175A patent/HUE048639T2/hu unknown
- 2011-10-27 EA EA201390387A patent/EA032139B1/ru not_active IP Right Cessation
- 2011-10-27 AU AU2011322581A patent/AU2011322581B2/en active Active
- 2011-10-27 ES ES18164175T patent/ES2787044T3/es active Active
- 2011-10-27 SM SM20200232T patent/SMT202000232T1/it unknown
- 2011-10-27 SG SG2013026828A patent/SG189869A1/en unknown
- 2011-10-27 RS RS20180624A patent/RS57260B1/sr unknown
- 2011-10-27 DK DK15195076.3T patent/DK3018145T3/da active
- 2011-10-27 PL PL18164175T patent/PL3412687T3/pl unknown
- 2011-10-27 JP JP2013535437A patent/JP5997168B2/ja active Active
- 2011-10-27 EP EP18164175.4A patent/EP3412687B1/en not_active Revoked
- 2011-10-27 LT LTEP18164175.4T patent/LT3412687T/lt unknown
- 2011-10-27 HU HUE15195076A patent/HUE037786T2/hu unknown
- 2011-10-27 PL PL15195076T patent/PL3018145T3/pl unknown
- 2011-10-27 SI SI201130709T patent/SI2632954T2/sl unknown
- 2011-10-27 ME MEP-2015-213A patent/ME02311B/me unknown
- 2011-10-27 LT LTEP15195076.3T patent/LT3018145T/lt unknown
- 2011-10-27 EP EP15195076.3A patent/EP3018145B1/en active Active
- 2011-10-27 PT PT181641754T patent/PT3412687T/pt unknown
- 2011-10-27 UA UAA201306486A patent/UA111175C2/uk unknown
- 2011-10-27 EP EP11787633.4A patent/EP2632954B2/en active Active
- 2011-10-27 TR TR2018/08019T patent/TR201808019T4/tr unknown
- 2011-10-27 NZ NZ701715A patent/NZ701715A/en unknown
-
2013
- 2013-04-24 IL IL225924A patent/IL225924A/en active IP Right Grant
- 2013-04-25 CL CL2013001138A patent/CL2013001138A1/es unknown
- 2013-05-27 CR CR20130245A patent/CR20130245A/es unknown
-
2015
- 2015-10-16 US US14/885,404 patent/US10696744B2/en active Active
-
2016
- 2016-01-29 CY CY20161100083T patent/CY1117155T1/el unknown
- 2016-02-17 SM SM201600050T patent/SMT201600050B/xx unknown
- 2016-06-01 JP JP2016110083A patent/JP6254220B2/ja active Active
-
2017
- 2017-11-29 JP JP2017228716A patent/JP6522722B2/ja active Active
- 2017-12-05 IL IL256110A patent/IL256110B/en active IP Right Grant
-
2018
- 2018-05-16 CY CY20181100508T patent/CY1120227T1/el unknown
- 2018-06-05 HR HRP20180882TT patent/HRP20180882T1/hr unknown
- 2018-07-25 IL IL260774A patent/IL260774B/en active IP Right Grant
-
2020
- 2020-05-08 CY CY20201100425T patent/CY1123251T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2632954T3 (da) | Midler og fremgangsmåder til behandling af dlbcl | |
| DK2493503T3 (da) | Doseringsplan for administrering af et cd19xcd3-bispecifikt antistof | |
| KR20140043350A (ko) | 잠재적 유해 효과의 위험에 처한 환자에게 cd19xcd3 이중특이적 항체를 투여하기 위한 투여 요법 | |
| HK1262611B (en) | Methods for treating dlbcl | |
| HK1262611A1 (en) | Methods for treating dlbcl | |
| HK1224678B (en) | Means and methods for treating dlbcl | |
| HK1224678A1 (en) | Means and methods for treating dlbcl | |
| HK1188229B (en) | Means and methods for treating dlbcl | |
| NZ719768B2 (en) | Means and methods for treating dlbcl |